Compounds
Mechanism of action, receptor targets, and molecular profiles for each research compound.
Retatrutide (LY3437943) is a synthetic triple incretin receptor agonist targeting GIP, GLP-1, and glucagon receptors. Mechanism and molecular data. RUO.
Tirzepatide is a synthetic dual GIP/GLP-1 incretin receptor agonist. Receptor targets, mechanism, molecular design, and accurate molecular data. Research use only.
BPC-157 is a synthetic 15-amino-acid partial sequence of body protection compound. Angiogenesis and tissue-repair pathways studied in models, plus molecular data. RUO.
TB-500 is a synthetic peptide related to thymosin β4, centered on its actin-binding domain. Mechanism, the TB-500 vs thymosin β4 distinction, and molecular data. RUO.
A research-use reference on CJC-1295, a synthetic GHRH(1-29) analog: receptor targets, the DAC vs no-DAC molecular distinction, and secretagogue mechanism.
A research reference on ipamorelin, a selective pentapeptide ghrelin-receptor (GHSR) agonist: receptor target, selectivity vs GHRP-2/GHRP-6, and molecular data.
A research reference on GHK-Cu, the copper-binding tripeptide Gly-His-Lys complexed with Cu(II): coordination chemistry and what the literature studies in matrix-remodeling models.
A research reference on IGF-1 LR3, an 83-residue IGF-1 analog with an Arg3 substitution and N-terminal extension: receptor binding, reduced IGFBP affinity, and half-life.
A molecular profile of the MOTS-c peptide: mitochondrial-derived peptide biology, the AMPK activation pathway, nuclear translocation under metabolic stress, and folate cycle interaction.
A research reference on the Melanotan II mechanism: a synthetic cyclic alpha-MSH analog and non-selective melanocortin receptor agonist (MC1R, MC3R, MC4R, MC5R).